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Abstract 
Intracranial ependymoma are relatively common paediatric 
brain tumours, but their eloquent location and high 
recurrence rate pose a significant challenge. Gross total 
resection or maximum safe resection followed by adjuvant 
radiotherapy are currently the standard recommended 
treatment, although there is still nearly 50% recurrence risk 
at 5 years. Chemotherapy has shown some promising 
results after recent advances in molecular understanding of 
ependymomas, but needs further evaluation before it could 
be added to the treatment regime. 
Keywords: Intracranial Ependymoma, Pediatric, Surgical 
Management. 
Introduction 
Ependymoma are neuroepithelial tumours, and comprise 8-
10% of all paediatric tumours.1 They are predominantly 
located in the brain in the posterior fossa (70% of the cases), 
but can be found in the supratentorial region and the spinal 
cord.2 Intracranial ependymoma are commonly present in 
the ventricles, but they can also occur in the cerebral cortex 
in the vicinity of the ependymal lining of the ventricles, and 
rarely can be purely cortical with no connection to the 
ventricular wall (Figure-1).3,4 The WHO classification system 
classifies ependymomas into 3 grades. Grade I are benign 
(myxopapillary), grade II tumours are also benign and can 
be divided into 4 sub-types (cellular, papillary, clear-cell and 
tanycytic), and grade III are malignant tumours (anaplastic). 
Historically, age at diagnosis, extent of surgical resection 
and pathological subtypes were considered important 
prognostic factors. However, there are incongruities in 
literature regarding relative importance of these clinical 
parameters. We have reviewed the literature to assess the 
current recommendations on the management of 
intracranial ependymomas, and to draw conclusions with 
regards to the outcomes. 
Review of Evidence 
Several factors influence the most appropriate management 
and outcomes of children with intracranial ependymomas. 
Surgical resection has been the mainstay of treatment with 
multiple objectives including tissue diagnosis, removing the 
mass effect from important neural structures and to open 
the CSF pathways for relieving hydrocephalus. However, 
complete excision poses a challenge considering eloquent 
location of these tumours. Consequently, gross total 
resection (GTR) is possible in only up to 50% of the cases.5 
Perilongo et al., had reviewed 92 children with 
ependymomas for extent of resection, and had reported 
better overall survival after GTR (69.8%) as compared to 
subtotal resection (STR) (32.5%).6 They had also reported that 
GTR group had a better impact on progression free survival 
(57% vs 11%).6 Similar conclusions were drawn by Horn et al., 
in a series of 83 patients.7 They reported that failure to 
achieve GTR, histological grade III tumours and less than 3 
years age at diagnosis were all factors that resulted in 
adverse outcomes in childhood intracranial ependymomas.7 
Cage et al., published a systematic review on outcomes in 
childhood intracranial ependymomas after combining extent 
of resection and histological grade.8 Patients with grade II 
ependymomas had better survival after GTR alone than with 
any other treatment modality. In patients with grade III 
ependymomas, STR with adjuvant radiation was associated 
with better outcomes than GTR. This was attributed to the 
fact that grade III tumours were more infiltrative with poorer 
anatomical boundaries, and thus, aggressive resection to 
achieve GTR caused more morbidity and resulted in poorer 
neurological outcomes, as compared to STR.8 
In a large multi-center retrospective analysis of 463 patients, 
Amanda et al., reviewed children with grade II and III 
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Figure-1: (a,b) MR T1 axial plain and contrast images of a 6 year old boy with a large 
heterogeneously enhancing ependymoma in the fourth ventricle, extending in to the 
cerebellopontine angle and brainstem.
intracranial ependymomas with long clinical and radiological 
follow-ups.9 Extent of resection, tumour sub-type and type of 
treatment were significantly associated with better overall 
survival in their study. GTR was superior to STR for 5-year 
survival (75 ± 5% vs. 54 ± 8%; p = 0.002).9 However, there was 
high recurrence rate within 10 years of diagnosis which 
brought overall survival to 61 ± 7% at 10 years; so GTR was not 
curative for all children.9 They proposed that GTR alone is not 
sufficient to treat children with intracranial ependymomas 
and recommended adjuvant treatments after surgery for 
better outcomes.9 Some studies have also proposed 'second-
look' surgery for residual ependymomas, however, a large 
cohort published by Italian investigators found no long-term 
significant difference in outcomes of children who 
underwent single surgery with adjuvant therapy, and those 
who underwent 'second-look' surgery.10 
Although radiation alone does not have a significant role in 
treatment of ependymomas, it has been shown to improve 
survival when coupled with surgical resection, particularly in 
cases where GTR is not possible, as shown in the study by 
Cage et al.8 Adjuvant radiotherapy is now part of the 
standard treatment protocol at most centers for children 
more than 3 years of age.11 Historically, prophylactic 
radiation was also administered to the whole neural axis to 
prevent recurrence. However, it has not proven to be of any 
benefit in preventing recurrence and distal metastasis. The St 
Jude RT-1 trial had recruited 88 children with ependymomas 
who were administered radiation and followed up for a 
median of 38.2 months. They concluded that limited volume 
local irradiation results in good disease control (3-year 
progression-free survival estimate was 74.7%  5.7%).12 
Chemotherapy till date, does not have a clearly defined role in 
management of intracranial ependymoma. Several studies 
have tried to assess the role of different regimens including 
vincristine, cyclophosphamide, etoposide, platinum 
derivatives and methotrexate, with promising results, but 
none have been able to post outcomes better than adjuvant 
radiotherapy.11 Its use is therefore currently limited to 
recurrent tumours not amenable for surgical resection. 
Nearly half the children with intracranial ependymomas 
will develop recurrence within five years, despite GTR and 
adjuvant radiation.13 Most of these recurrences are at the 
primary tumour site. The recommended treatment 
protocol for recurrent ependymomas involves surgical 
resection wherever possible and re-irradiation often using 
proton-beam therapy, with some centers including 
chemotherapy as well.11 
Conclusion 
Extent of resection is the prime prognostic factor followed by 
age at presentation, both of which have a direct relation to 
the favourability of outcomes. GTR followed by adjuvant focal 
radiation remains the optimal choice for paediatric cranial 
ependymomas and has significantly improved the overall 
survival and progression-free survival over 5 years follow ups. 
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